We are discovering tomorrow's drugs with Artificial Intelligence
Kantify uses Artificial Intelligence to discover breakthrough therapies that
change patients' lives.
Our cutting-edge AI platform, Zeptomics, identifies safe and effective drugs in silico, with lightning speed, for any disease.
Our cutting-edge AI platform, Zeptomics, identifies safe and effective drugs in silico, with lightning speed, for any disease.
Humanity needs to make a leap forward in drug discovery
There are not enough therapies
Ninety-five percent of diseases still do not have an approved therapy.
As such, there is an urgent need to significantly accelerate humanity's
ability to find drugs that are safe and effective.
AI can make the difference
We believe Artificial Intelligence (AI) is the key to this acceleration,
and will help us to live better, healthier, and longer lives.
We are building AI that improves human health
Zeptomics is our AI drug discovery platform, which we use to find and
design drugs for a wide variety of serious diseases. We focus our
efforts on small molecule drugs and targeted protein degraders.
Segolene Martin
Chief Executive Officer
Kantify
When we first started getting the first lab validations of our drug discovery platform, Zeptomics, we couldn't believe how much of a leap we had made over traditional drug discovery approaches. What took giant pharmaceutical companies years, took us weeks, using a fraction of the resources.
We know today that Zeptomics is hugely powerful and has the potential to truly revolutionize human health. There's a great moral responsibility that comes with this realization. We think every day how we can maximize the impact, for the good of all, of this incredible technology we continue to develop.
Our technologies help us to discover new boundaries of biology
Less work to find better drugs
Through experimental data, we've shown that Zeptomics has an
unprecedented ability to find effective modulators of any biological
target. On average, more than 25% molecules we test act on our
biological target of interest - a significant increase over classical
screens where fewer than 0.01% molecules show any promise.
Capable of treating more than a single disease
We have successfully used Zeptomics to tackle a wide variety of
diseases, including in the field of oncology, neurology, muscular
diseases, and even in plant health. This unprecedent breadth of ability
shows that Zeptomics has achieved a new threshold of understanding of
novel biology and chemistry.
Designing drugs with fewer side effects
One of Zeptomics' unique capabilities is to accurately predict the
pharmacodynamic and phamacokinetic profile of drugs - information that
is crucial to understand likely side effects of drugs. In doing so, we
can pro-actively select the most promising drugs before any chemical
synthesis happens.
Helping us explore new frontiers of biological understanding
Zeptomics is starting to uncover a wide variety of novel biological
mechanisms and druggable targets of a wide variety of diseases. In doing
so, we create significant new opportunities for targeted therapies which
are safer and more effective.
You can help us make a difference
Find out more about the drugs we are designing
We are developing a pipeline of small molecules and degraders in a
variety of disease areas, including neurology, neuromuscular diseases,
cardiology and oncology.
Learn about the technology we are developing
Zeptomics, our AI drug discovery platform, helps us to discover and
design safe and effective small molecule drugs and targeted protein
degraders at a fraction of the cost and time.
Get to know the people of Kantify
We are a mission driven company at the crossroads of Artificial
Intelligence and Biotechnology. We have strong values and use our
brains to make a difference in patients' lives.
Partner with us
Kantify has a strong culture of collaboration with biotech and
academic partners. Discover how to partner with Kantify and accelerate
or unlock your drug hunting project.
News
Updates about our projects, team and technologyKantify reveals promising results in sarcoma at ESMO
Tue 02 Apr 2024
Kantify Unveiled Promising Results in Liposarcoma Drug Discovery thanks to AI at ESMO Sarcoma and Rare Cancer Congress 2024
Nicolas Maignan appointed Chief Operating Officer of Kantify
Tue 19 Mar 2024
Announcement: Nicolas Maignan is officially appointed COO of Kantify
AI for Healthcare panel at the Pharma.be General Assembly
Thu 14 Mar 2024
Kantify was invited at the pharma.be special panel on AI for Healthcare
Poster at ESMO : AI for target and drug discovery in sarcoma
Mon 11 Mar 2024
Kantify will share its latest results on rapid identification of novel targets and polypharmacological compounds for liposarcoma treatment, thanks to AI
Insights
Insights about drugs, biology, chemistry, and machine learningAI and Drug Repurposing: Farewell, serendipity?
Thu 17 Aug 2023
Our pledge to make therapies available for patients, faster, and why Artificial Intelligence is the key for small molecule repurposing
ADMET prediction with Artificial Intelligence : Publication
Fri 29 Apr 2022
Peer reviewed publication "Dual Blockade of Misfolded Alpha-Sarcoglycan Degradation by Bortezomib and Givinostat Combination"
Artificial Intelligence for Targeted Protein Degradation
Mon 14 Mar 2022
Discover how Kantify’s AI -based drug discovery tool, Zeptomics, accelerates the discovery of promising Targeted Protein Degraders (PROTAC, DUBTAC, LYTAC,...),